ALX ONCOLOGY HOLDINGS INC Payments to Acquire Investments
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Payments to Acquire Investments of $130.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC payments to acquire investments for the quarter ending 2026-06-30 was $5.75M, a 77.35% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC payments to acquire investments for the quarter ending 2026-03-31 was $124.49M, a 689.13% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC payments to acquire investments for the quarter ending 2025-12-31 was $5.97M, a 34.43% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC payments to acquire investments for the quarter ending 2025-09-30 was $4.44M, a 49.02% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC payments to acquire investments for fiscal 2025 was $51.59M, a 51.96% decline from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC payments to acquire investments for fiscal 2024 was $107.41M, a 56.45% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC payments to acquire investments for fiscal 2023 was $246.63M, a 34.54% decline from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC payments to acquire investments for fiscal 2022 was $376.79M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $130.24M 10-Q · filed 2026-08-06 | $136.21M derived: sum of 3 quarters · filed 2026-08-06 | $140.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $124.49M 10-Q · filed 2026-05-08 | $130.46M derived: sum of 2 quarters · filed 2026-05-08 | $134.90M derived: sum of 3 quarters · filed 2026-05-08 | $160.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $10.42M derived: sum of 2 quarters · filed 2026-03-09 | $35.82M derived: sum of 3 quarters · filed 2026-08-06 | $51.59M 10-K · filed 2026-03-09 |
| 2025-09-30 | $4.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $29.84M derived: sum of 2 quarters · filed 2026-08-06 | $45.62M 10-Q · filed 2025-11-07 | $50.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $41.18M 10-Q · filed 2026-08-06 | $45.62M derived: sum of 3 quarters · filed 2026-08-06 | $54.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $15.78M 10-Q · filed 2026-05-08 | $20.22M derived: sum of 2 quarters · filed 2026-05-08 | $28.93M derived: sum of 3 quarters · filed 2026-05-08 | $91.90M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $4.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $13.16M derived: sum of 2 quarters · filed 2026-03-09 | $76.12M derived: sum of 3 quarters · filed 2026-03-09 | $107.41M 10-K · filed 2026-03-09 |
| 2024-09-30 | $8.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $71.68M derived: sum of 2 quarters · filed 2025-11-07 | $102.96M 10-Q · filed 2025-11-07 | $177.97M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $62.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $94.25M 10-Q · filed 2025-08-12 | $169.26M derived: sum of 3 quarters · filed 2026-03-09 | $222.15M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $31.29M 10-Q · filed 2025-05-08 | $106.30M derived: sum of 2 quarters · filed 2026-03-09 | $159.18M derived: sum of 3 quarters · filed 2026-03-09 | $205.71M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $75.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $127.90M derived: sum of 2 quarters · filed 2026-03-09 | $174.43M derived: sum of 3 quarters · filed 2026-03-09 | $246.63M 10-K · filed 2026-03-09 |
| 2023-09-30 | $52.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $99.42M derived: sum of 2 quarters · filed 2024-11-07 | $171.62M 10-Q · filed 2024-11-07 | $232.59M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $46.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $118.73M 10-Q · filed 2024-08-12 | $179.70M derived: sum of 3 quarters · filed 2025-03-06 | $216.31M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $72.20M 10-Q · filed 2024-05-09 | $133.17M derived: sum of 2 quarters · filed 2025-03-06 | $169.79M derived: sum of 3 quarters · filed 2025-03-06 | $265.66M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $60.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $97.58M derived: sum of 2 quarters · filed 2025-03-06 | $193.46M derived: sum of 3 quarters · filed 2025-03-06 | $376.79M 10-K · filed 2025-03-06 |
| 2022-09-30 | $36.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $132.49M derived: sum of 2 quarters · filed 2023-11-13 | $315.82M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $95.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $279.21M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $183.33M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |